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One sentence summary: 
KIR2DS2, an activating natural killer cell receptor recognizes highly conserved peptides 
derived from the RNA helicases of pathogenic flaviviruses. 
 
Abstract 
Killer cell immunoglobulin-like receptors (KIR) are rapidly evolving species-specific natural 
killer cell receptors associated with protection against multiple different human viral 
infections. We report that the activating receptor KIR2DS2 directly recognizes viral peptides 
derived from conserved regions of flaviviral superfamily 2 RNA helicases in the context of 
MHC class I.  The peptide LNPSVAATL, from the HCV helicase, binds HLA-C*0102 leading 
to NK cell activation through engagement of KIR2DS2. Similarly, HLA-C*0102 presents 
highly conserved peptides from the helicase motif 1b region of related flaviviruses, including 
dengue, Zika, yellow fever and Japanese encephalitis viruses, to KIR2DS2.  These flaviviral 
peptides all contain an “MCHAT” motif, which is present in 61 out of 63 flaviviruses. 
LNPSVAATL is also highly conserved across HCV genotypes and mutation of this epitope is 
poorly tolerated by HCV. KIR2DS2 recognizes endogenously presented helicase peptides 
and KIR2DS2 is sufficient to inhibit HCV and dengue virus replication in the context of HLA-
C*0102.  Targeting short, but highly conserved, viral peptides provide non-rearranging innate 
immune receptors with an efficient mechanism to recognize multiple, highly variable 
pathogenic RNA viruses. 
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Introduction 
Natural killer (NK) cells are critical determinants in the innate immune response to a number 
of globally-important viral infections including HIV, hepatitis C virus, dengue and 
Chikungunya virus (1-4). Their functions are controlled by non-rearranging immune receptors 
many of which are well conserved, consistent with a role in innate immunity.  The killer cell 
immunoglobulin-like receptors (KIR) are a rapidly evolving family of NK cell receptors that 
exhibit substantial population diversity.  They have peptide:MHC class I specificity, and 
certain combinations of KIR and their MHC class I ligands have been associated with the 
outcome of a number of viral infections including, the inhibitory receptor KIR2DL3 and 
hepatitis C, and the activating receptor KIR3DS1 and HIV (4, 5).   
 
The KIR have evolved rapidly since the divergence of humans from chimpanzees, in a 
manner indicative of pathogen-mediated selection.  One mechanism by which the KIR 
contribute to recognition of pathogens has been identified for inhibitory KIR as related to 
downregulation of MHC class I (6).   Conversely, there is little understanding of how 
activating KIR can recognize pathogens.  Recent work has shown that KIR3DS1, which 
shares sequence homology with HLA-B specific inhibitory KIR3DL1, binds open conformers 
of HLA-F and this may result in inhibition of HIV infection (7).  However, the mechanisms by 
which the activating KIR with putative HLA-C ligands recognize pathogens remain enigmatic  
(8). 
 
Human KIRs bind subsets of HLA class I ligands and engage both the HLA class I heavy 
chain and the bound peptide. Furthermore, changes in the peptide content of HLA class I can 
abrogate KIR-mediated inhibition of NK cells, demonstrating a mechanism for KIR-
associated NK cell activation distinct from HLA class I down-regulation (9).  KIR2DL2 and 
KIR2DL3 are inhibitory KIRs with a predominant specificity for the group 1 HLA-C allotypes 
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(HLA-C1).  Both these inhibitory receptors have similar specificities for peptide:MHC, as 
could be predicted from the high sequence homology of their extra-cellular domains (10).   
The activating receptor KIR2DS2 also has ~98% amino acid identity in the ligand binding 
domains to KIR2DL2 and KIR2DL3, and is in strong linkage disequilibrium with KIR2DL2.  
Despite this shared sequence homology, it has been difficult to identify binding of KIR2DS2 
to HLA-C.  One of the key differences between KIR2DS2 and KIR2DL2/KIR2DL3 is the 
presence of a tyrosine, as compared to a phenylalanine, residue at position 45 and this is 
thought to significantly affect binding of KIR2DS2 to HLA-C (11).  Low level binding of 
KIR2DS2 to HLA-C in combination with an Epstein-Barr virus (EBV) peptide was detected by 
surface plasmon resonance (12).  More recently, KIR2DS2 has been demonstrated to have 
peptide specific binding to HLA-A*1101, an HLA class I allele which binds a number of 
diverse KIR including KIR2DS4 and KIR3DL2 (13, 14).   KIR2DS2 has also been shown to 
bind cancer cell lines in a ß2-microglobulin independent manner (15).  Nonetheless, based 
on the high sequence homology of KIR2DS2 with KIR2DL2 and KIR2DL3, we sought to 
determine if KIR2DS2 was also an HLA-C restricted peptide specific receptor. 
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Results 
KIR2DS2 recognizes the HCV peptide LNPSVAATL in the context of HLA-C*0102 
Immunogenetic analyses by Thio et al. have identified HLA-C*0102 to be protective in the 
context of chronic HCV infection (16).  Based on this observation, we used HLA-C*0102 as a 
template allele to identify peptides from HCV to determine how they may modulate NK cell 
function.   We screened the HCV genotype 1b genome (AF313916.1) for potential HLA-
C*0102 binding peptides using the algorithms ADT, Net-MHC pan and KISS, coupled with a 
manual scan using the known HLA-C*0102 motif xxPxxxxxL (17).  We identified eight 
peptides for further study (Table S1).  We used the TAP-deficient 721.174 cell line, which 
expresses HLA-C*0102 naturally, to present the HCV peptides in binding and functional 
assays. These cells are deficient in the TAP protein and hence can be used to present 
exogenous peptide to lymphocytes (18).   Analysis of binding to HLA-C*0102 using peptide 
titrations demonstrated that four peptides (LLPRRGPRL, AQPGYPWPL, LSPHYKVFL, 
RAYLNTPGL) had a low affinity for HLA-C*0102, not reaching saturation point at 100µM, one 
(VLPCSFTTL) had an affinity comparable to the endogenously presented peptide 
VAPWNSLSL, and the remainder (LSPRPVSYL, LNPSVAATL, ARPDYNPPL) had an 
intermediate affinity for HLA-C*0102 (Fig. S1).  
 
In order to determine how these peptides modulate NK cell reactivity, we used the 721.174 
cells. The CD158b epitope includes the KIR2DL2, KIR2DL3 and KIR2DS2 proteins and 
therefore marks NK cells with specificity for HLA-C*0102.  We identified one peptide 
LLPRRGPRL that inhibited the activation of CD158b+ NK cells, but the remainder of the 
peptides had no effect on NK cell degranulation relative to the “no peptide” control (Fig. S2). 
In the absence of peptide there is activation of CD158b-positive NK cells by 721.174 such 
that 25-30% NK cells express CD107a (Fig. 1A and 1B).  In order to identify specific 
activation of KIR2DS2-positive NK cells, we reduced the background activation of CD158b-
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positive NK cells by using an inhibitory peptide VAPWNSFAL, and testing the ability of the 
peptides to activate NK cells relative to this strong inhibitory signal. We used VAPWNSFAL 
as it was the strongest inhibitory peptide that we identified in a peptide screening assay for 
KIR binding and NK cell inhibition (9).  From an initial screening assay using three 
unselected donors, we identified two peptides, LNPSVAATL (LNP) and VLPCSFTTL (VLP), 
which activated CD158b+ NK cells relative to VAPWNSFAL alone (Fig. 1A).   
 
As CD158b marks the inhibitory receptors KIR2DL2 and KIR2DL3, and the activating 
receptor KIR2DS2, we stratified the donors by KIR genotype: KIR2DL2+KIR2DS2+KIR2DL3- 
(KIR2DL2/S2 homozygous) and KIR2DL2-KIR2DS2-KIR2DL3+ (KIR2DL3 homozygous).   
VLP activated CD158b-positive NK cells relative to VAPWNSFAL alone in both 
KIR2DL2+/S2+/L3-  donors and KIR2DL2-/S2-/L3+  donors (Fig. 1B). In contrast, the effect of 
LNP on CD158b-positive NK cells was present for KIR2DL2+/S2+/L3- donors, but not 
KIR2DL2-/S2-/L3+ donors (Figs. 1B and 1C).  Conversely no differences were found for the 
CD158b-negative NK cells for either groups of donors (Fig. 1D). This indicates that the 
increase in degranulation was related either to KIR2DL2 or to KIR2DS2.  KIR2DL2+ NK cells 
are less responsive to changes in peptide content of MHC class I than KIR2DL3+ NK cells 
(19). Therefore, we reasoned that this change in degranulation was related to NK cell 
activation through engagement of KIR2DS2.   
 
In order to map this specificity more closely, we cloned NK cells from a 
KIR2DL2+KIR2DS2+KIR2DL3- donor.  We tested three KIR2DS2+ NK cell clones against the 
721.174 cells (Fig. S3).  We found that although LNP augmented lysis of 721.174 cells by 
KIR2DS2-positive NK cell clones, background levels of killing against targets in the absence 
of peptide were high.  We therefore sought an alternative strategy using the KIR-negative cell 
line NKL.  We transfected NKL cells with either KIR2DS2 or KIR2DL2 and used them as 
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effector cells.  We also generated 721.221 target cells stably expressing either HLA-C*0102 
alone or HLA-C*0102 and LNP together.  In cytotoxicity assays NKL-2DS2 cells lysed 
721.221:C*0102 cells to a similar level as untransfected NKL cells, but lysed LNP expressing 
721.221:C*0102 cells significantly better than 721.221:C*0102 cells without LNP (Fig. 1E 
and 1F). Thus LNP specifically activates NKL cells expressing KIR2DS2, but has no effect of 
KIR2DL2-positive NK cells.  As there were similar levels of killing of 721.221:C*0102 cells by 
NKL-2DS2 and NKL cells, this observed increased level of lysis is not related to a 
generalized increase in baseline cytolytic activity of the NKL-2DS2 cell line against 721.221 
cells, but to specific recognition of the combination of LNPSVAATL and HLA-C*0102 by 
KIR2DS2. 
 
LNPSVAATL engages KIR2DS2, but not KIR2DL2 
In order to confirm the reactivity of KIR2DS2 with HLA-C*0102:LNP, we made a KIR2DS2 
tetramer.  In a binding assay we detected low-level, but consistent and significant binding of 
the KIR2DS2 tetramer to the peptide LNPSVAATL (p<0.001) as compared to the naturally 
eluted peptide VAPWNSLSL and also KIR2DS2 binding to the peptides VAPWNSATL and 
VAPWNAATL (Fig. S4).  This is in line with previous observations that positions seven and 
eight of the HLA class I peptide are important for KIR binding, as has been observed for the 
inhibitory KIR.  As the binding of the tetramer was at a low level (~1.5 times background), we 
used a clustering assay to determine if a cell-cell contact assay could detect specific 
recognition of LNP by KIR2DS2. Transfectants of the Ba/F3 cell line expressing either 
KIR2DL2 or KIR2DS2 were used to investigate receptor clustering (20).  These are murine B 
cells and hence do not express other human NK cell activating receptors.  The Ba/F3 
transfectants were co-incubated with 721.174 cells pulsed with peptide.  LNP induced 
clustering of KIR2DS2, but not KIR2DL2, whereas the inhibitory peptide VAPWNSFAL 
induced clustering only of KIR2DL2 (Figs. 2A and B).   
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To further determine if the interaction of LNP with KIR2DS2 led to NK cell activation, we 
studied signalling in the NKL cell lines.  Activating KIRs transduce positive signals through 
the adapter molecule DAP12 and antibody cross-linking of KIR2DS2 has been shown to lead 
to DAP12 phosphorylation (20). We therefore tested whether LNP could lead to activation of 
NK cells via DAP12. Immunoprecipitation (IP) of KIR2DS2 from NKL-2DS2 cells co-cultured 
with 721.174 cells in the presence or absence of peptide, demonstrated LNP-induced 
enhanced tyrosine phosphorylation of the co-immunoprecipitated DAP12, consistent with NK 
cell activation (Fig. 2C).  Moreover, the presence of LNP augmented tyrosine 
phosphorylation of the downstream guanine nucleotide exchange factor Vav1 in NKL-2DS2 
cells, but had no effect on KIR2DL2 signalling in NKL-2DL2 cells (Fig. 2D).  We further 
tested whether KIR2DL2 could bind LNP in the context of C*0102 using a KIR2DL2-Fc fusion 
construct.  Consistent with the functional experiments, there was no direct binding of a 
KIR2DL2 fusion construct to LNP-pulsed 721.174 cells (Fig. 2E).  Taken together these data 
demonstrate that LNP specifically activates KIR2DS2+ NK cells through the DAP12-Vav1 
pathway, but has no effect on KIR2DL2+ NK cells, establishing it as a peptide that 
discriminates an activating KIR from its closely related inhibitory counterpart.  
 
KIR2DS2 recognizes LNPSVAATL in the context of HCV infection 
Having observed that KIR2DS2 recognized LNP in the context of HLA-C*0102 as both 
exogenously and endogenously loaded peptide, we wanted to test if it could also recognize 
LNP in the context of HCV replication.  To do this we generated an HUH7 cell line stably 
expressing the HCV sub-genomic replicon N17 (JFH1ΔE1E2-luc) and also transfected in 
HLA-C*0102.  N17 contains the full length HCV genome without the envelope proteins, and 
replicates as a wild-type virus, and hence it is considered that it produces proteins to a 
similar level as wild-type virus (21). It also has a luciferase gene incorporated within the HCV 
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construct to allow assessment of replication by a luciferase assay.  HUH7 is a hepatoma cell 
line that expresses HLA-A*1101, but not HLA-B or HLA-C and is permissive for HCV 
replication (22).   We used the transfected NKL cell lines to assess the potential for KIR2DS2 
to specifically inhibit replication of N17 in this system. NKL-2DS2 inhibited HCV replication at 
low E:T ratios (0.01:1) in the HLA-C*0102-expressing HUH7 cells to a significantly greater 
extent than parental NKL cells or NKL-2DL2 cells. (Fig. 3A right panel).  Conversely in the 
parental HUH7 cell line, that is HLA-C negative, NKL, NKL-2DL2 and NKL-2DS2 inhibited 
HCV replication to similar levels (Fig. 3A) suggesting that KIR2DS2 requires the presence of 
HLA-C to inhibit HCV replication.   
 
To investigate the role of the LNP peptide in the inhibition of HCV replication by KIR2DS2 we 
made non-conservative aspartate variants of the N17 replicon at the HLA-binding anchor 
residues P3 and P9, and the putative KIR binding residues, P7 and P8 (17).  Mutation of P9 
retained HCV replication to wild-type levels, but mutation of the P3, P7 or P8 residues in this 
epitope profoundly inhibited replication of the N17 replicon viral RNA to a level similar as that 
of the non-replicating control which has a lethal “GND” polymerase mutation (23) (Fig. 3B).   
We therefore performed inhibition of replication assays using only the P9 leucine to aspartate 
N17 variant (L9D). In these assays there was no specific effect of KIR2DS2 noted (Fig. 3C) 
suggesting that KIR2DS2 recognition of HCV in the context of HLA-C*0102 is dependent on 
the LNP epitope. 
 
To test the HLA-C specificity of this response we transfected HUH7 cells, expressing either 
the N17 replicon or the mutated N17-L9D replicon, with HLA-C*0304.  NKL-2DS2 inhibited 
HCV replication to a significantly greater extent than NKL-2DL2 or the parental NKL cell lines 
at all E:T ratios tested (Fig. 3D).  However, this was not related to the LNP peptide as NKL-
2DS2 also inhibited replication of the N17-L9D replicon to a similar extent.  Importantly LNP 
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was unable to stabilize HLA-C*0304 in a peptide stabilization assay using 721.221:HLA-
C*0304 cells transfected with ICP47 which blocks transporter associated with antigen 
processing (TAP) function (Fig. 3E).  Furthermore, using the same cell lines to present 
peptide, LNP did not engage KIR2DS2 in the context of HLA-C*0304 in tetramer-binding or 
Vav1 phosphorylation assays (Fig. 3F and 3G).  In order to generate a positive control 
peptide for this experiment, we tested P7 and P8 derivatives of the naturally processed HLA-
C*0304-binding peptide, GAVDPLLAL, guided by our current work and also that of Liu et al 
(13, 24).  GAVDPLLAL, GAVDPLAWL and GAVDPLATL all stabilised HLA-C*0304, but only 
GAVDPLAWL induced binding of the KIR2DS2 tetramer to HLA-C*0304 and Vav1 
phosphorylation (Fig. 3E-G).  Thus KIR2DS2 has a broad peptide:HLA-C specificity and it is 
likely that there are other HCV peptides that can be presented by HLA-C*0304 and 
recognized by KIR2DS2.   
 
 
LNPSVAATL is a highly conserved peptide 
HCV is an RNA virus with high sequence variability due to a lack of a proof-reading capability 
of its RNA polymerase.  We therefore assessed whether there was a clinical correlate to the 
defective replication of replicons with LNP variants. We observed that the LNP epitope is 
highly conserved across HCV genotypes which in general differ by up to 30% in sequence 
identity (Table S2).  Indeed, genotype 5 HCV, the only genotype with a consistent variation 
of this epitope, has a leucine to phenylalanine variant at P9 consistent with our finding in the 
replication assays that variation at P9 of the LNP epitope does not affect HCV replication.  
Furthermore the LNP epitope is conserved across 878 (98.5%) of the 891 HCV NS3 
sequences deposited in the Los Alamos HCV database (http://hcv.lanl.gov).  Thus, a lack of 
natural variation in this region implies that, in vivo, mutation of LNP is relatively poorly 
tolerated and marks it as a viable target for a non-rearranging immune receptor.  
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Furthermore, structural analysis demonstrates LNP is located within the RNA helicase 
domain of the HCV NS3 protein in the Ia motif and that the LNP peptide is in the RNA 
binding region of this motif, consistent with its relative lack of variation (25).  Thus, it is in a 
critical functional region of HCV. 
 
To investigate if KIR2DS2 was associated with the outcome of HCV infection on a genetic 
basis, we performed logistic regression analysis of: putative activating KIR:HLA combinations 
(KIR2DS1:HLA-C2, KIR2DS2:HLA-A*11, KIR2DS2:HLA-C1, KIR3DS1:HLA-BBw4) and control 
activating KIR:HLA combinations (KIR2DS1:HLA-C1, KIR2DS2:HLA-C2), together with key 
protective (KIR2DL3:HLA-C1 homozygosity) and susceptibility (KIR2DS3) factors in our UK 
Caucasian population with resolved (n=120) or chronic (n=216) HCV infection (4). KIR2DS2 
in combination with HLA-C1 was protective against chronic HCV infection (p=0.033, 
OR=2.06 95% CI=1.06-4.02), but no association was found between KIR2DS2 in 
combination with HLA-A*11 and the outcome of HCV infection (Table 1).  We also noted that 
KIR3DS1 in combination with HLA-BBw4 was protective, but none of the control combinations 
were associated with the outcome of HCV infection.  Thus, in HCV infection, group 1 HLA-C 
alleles are protective in combination with both KIR A (KIR2DL3) and KIR B (KIR2DS2) 
centromeric haplotypes.  
 
A highly conserved peptide from multiple flaviviruses contains the “AT” KIR2DS2-
binding motif 
HCV is a member of the Flaviviridae family, which incorporates viruses within the genus 
Flavivirus that include globally important pathogens such as Zika, dengue, yellow fever, 
Japanese encephalitis and West Nile viruses.  Similar to HCV, these viruses all encode an 
RNA helicase belonging to superfamily 2 (SF2) as a C-terminal domain of the NS3 protein 
(26).  However, as the LNP peptide is not conserved amongst these viruses we sought 
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additional HLA-C*0102-binding peptides that may engage KIR2DS2.  We screened the viral 
genomes from these viruses using NET MHCpan 2.8 and a percentage rank cut-off for 
binding of 2.  We identified putative HLA-C*0102 -binding peptides from the helicases of 
these viruses that had both the HLA-C*0102 binding motif and the “AT” KIR2DS2-binding 
motif (Table S3).  These peptides all contained a highly conserved MCHAT sequence from 
the NS3 Ib motif that is completely conserved amongst 61 out of 63 viruses within the genus 
Flavivirus regardless of the species tropism of the virus (Fig. 4 and Table S4).   Interestingly, 
using a blast search (https://blast.ncbi.nlm.nih.gov/Blast.cgi), this sequence is not found 
intact within the human genome.  
 
KIR2DS2 recognizes conserved peptides from Flavivirus helicases  
We then assessed KIR2DS2 binding to peptides containing this conserved “MCHAT” peptide 
motif.  We identified representative peptides from key human pathogens including Zika virus 
(ZIKV) and dengue viruses (DENV) (IVDLMCHATF: both ZIKV NS3255-264 [BAP47441.1] and 
DENV NS3256-265 [ACK57817.1]), yellow fever virus (YFV) (VIDAMCHATL: YFV NS3255-264   
[AIZ07887.1]) and West Nile virus (WNV) and Japanese encephalitis viruses (JEV) 
(IVDVMCHATL: both WNV NS3255-264 [AFI56984.1] and JEV NS3255-264 [ABU94628.1]. We 
used these peptides to load 721.174 cells and demonstrated that at 200µM in flow cytometry 
assays these peptides induced binding to KIR2DS2-tetramers, with enhanced binding of 
KIR2DS2 by the ZIKV and DENV peptide, IVDLMCHATF (Fig. 5A).   
 
Our binding and functional experiments all used the KIR2DS2*001 allele and we therefore 
tested if allelic diversity of KIR affected KIR2DS2-mediated peptide recognition.  We tested 
the alleles KIR2DS2*007 and KIR2DS*008, which have polymorphisms in the ligand binding 
domains compared to KIR2DS2*001 (27). Using a tetramer binding assay we found that 
these allelic variants had a similar peptide specificity as KIR2DS2*001 (Fig. S5).  Thus allelic 
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diversity of KIR2DS2 did not influence recognition of HLA-C*0102 presented peptides by 
KIR2DS2. 
 
To test if these flaviviral peptides could activate NK cells we tested Vav1 phosphorylation in 
NKL-2DS2 cells.  721.1.74 were loaded with peptide and co-cultured with NKL-2DS2 cells.  
The flaviviral peptides that bound KIR2DS2 also induced Vav1 phosphorylation in NKL-2DS2 
cells (Fig. 5B).  We next generated a 721.221 transfectant stably expressing HLA-C*0102 
and the DENV/ZIKV peptide IVDLMCHATF.  We co-cultured these cells with NKL, NKL-2DL2 
and NKL-2DS2 cells.  Endogenous expression of IVDLMCHATF with HLA-C*0102 resulted in 
augmented lysis of 721.221 transfectants by NKL-2DS2 as compared to lysis of 721.221 
expressing HLA-C*0102 alone, but did not augment lysis by NKL or NKL-2DL2 cells (Fig. 
5C).     
 
To test the potential for KIR2DS2 to recognize native dengue virus we used a dengue 
replicon system	 (28).  The DENV genome replicates at a slightly lower level in human 
embryonic kidney (HEK) cells expressing the replicon than during a wild-type virus infection, 
but with a slight overexpression of protein over time (Fig. S6). HEK cells stably expressing 
the dengue replicon were transiently transfected with HLA-C*0102 or HLA-C*0304.  NKL-
2DS2 preferentially lysed DENV replicating HEK cells transfected with HLA-C*0102 as 
compared to HEK:HLA-C*0102 not expressing DENV, and also HEK cells expressing both 
DENV and HLA-C*0102 cells as compared to those just expressing DENV (Fig. 5D, 5E and 
Fig. S7).  However, we did not observe KIR2DS2-specific lysis of HEK cells expressing 
DENV and HLA-C*0304 (Fig. 5F).  Thus in addition to HCV, KIR2DS2 also recognizes 
flavivirus helicase peptides in the context of HLA-C*0102.  
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Analysis of the crystal structures of the NS3 helicases of both HCV and DENV complexed 
with nucleic acids representative of the viral RNA indicate that similar to the HCV LNP 
epitope, the IVDLMCHATF peptide directly contacts the viral nucleic acid (Fig. 5G). 
Furthermore the NS3 helicases of DENV, ZIKV and JEV are all highly conserved, with this 
peptide occupying a similar position in all crystal structures (25, 29-31). Thus KIR2DS2 
recognizes highly conserved peptide motifs, within the helicases of the Flaviviridae, which 
are directly involved in RNA binding and under extreme constraints on their ability to mutate.  
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Discussion 
These data demonstrate that KIR2DS2 functions as an antigen specific receptor that 
recognizes conserved peptides from the Flaviviridae family of viruses.  We have shown that 
KIR2DS2 recognizes: a peptide derived from the helicase 1a region of HCV, which is highly 
conserved amongst HCV genotypes; and also a conserved peptide sequence from 
flaviviruses, including the dengue and Zika viruses.  The peptides are all have alanine and 
threonine at the the C-terminus -1 and -2 positions respectively, and within the flaviviral 
sequences, these two amino acids form part of an MCHAT motif within the helicase 1b 
region and which is conserved in 61 out of 63 flaviviruses.  The peptides can be 
endogenously present by HLA-C*0102, and the combination of the HCV peptide 
LNPSVAATL and HLA-C*0102 is sufficient for KIR2DS2 to inhibit replication in vitro.  Thus 
KIR2DS2 has some functions analogous to a T cell receptor in recognizing peptide:MHC, but 
has a broad specificity in that is also recognizes HLA-C*0304 and peptide (12).  Binding to 
different peptides derived from pathogens, and also different HLA class I molecules is a likely 
pre-requisite for KIR2DS2 to have reached its current population frequency of approximately 
50%.  Our experiments suggest that an additional HCV peptide may be presented by HLA-
C*0304 to KIR2DS2.  However, further work is required to define the complete specificity of 
this receptor. 
 
A broad specificity for KIR2DS2 is consistent with our understanding of how inhibitory KIR 
engage HLA class I (10). The recognition of different peptides and HLA class I allotypes is 
facilitated by the motif-based recognition of HLA class I by KIR, in which the KIR:HLA 
interface is stabilized by salt bridges (32) and peptide selectivity is determined by the C-
terminus -1 and -2 residues of the peptide.  Thus although the HCV and DENV peptides 
share only 2 residues, both are recognized by KIR2DS2 in the context of the same HLA class 
I molecule.  This is consistent with the mode of binding observed for the HLA-C specific 
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inhibitory KIR.  KIR2DS2 thus demonstrates similarities in binding properties to the inhibitory 
KIR, but with distinct peptide selectivity from its inhibitory counterparts, KIR2DL2 and 
KIR2DL3.  One concern is that a broad peptide specificity may lead to autoreactivity and 
interestingly, there is an association of KIR2DS2 with the autoimmune disease systemic 
sclerosis  and rheumatoid vasculitis (33, 34).  
 
We have studied ligands for KIR2DS2 in vitro, and analysis of our HCV population 
demonstrated an in vivo correlation of KIR2DS2 with the outcome of HCV infection.  
However, to date there are no studies that demonstrate an in vivo role for KIR2DS2 in 
flavivirial infection. In an immunogenetic study there was an under-representation of 
KIR2DS2 in dengue virus (39.0%) infected individuals as compared to healthy controls 
(64.8%) (35), suggesting a positive association of KIR2DS2 with dengue virus clearance. 
Furthermore, during acute dengue virus infection NK cells are activated in vivo, but testing of 
KIR2DS2-positive NK cells in this context is difficult because of the lack of specific reagents 
that distinguish KIR2DS2 from KIR2DL2/3.  Thus further in vivo work is required to determine 
whether KIR2DS2-positive NK cells are specifically activated during acute flaviviral 
infections. 
 
Nonetheless higher KIR2DS2 gene frequencies are seen in populations from Central and 
Southern Africa where flaviviral infections are more common (36).  Furthermore, within the 
Amerindian population both the A and the B KIR haplotypes have been maintained (37).  
This balancing selection is thought to be due to the combined effects of the KIR B haplotype 
protecting against pregnancy induced disease and the KIR A haplotype protecting against 
infectious disease.  However, the genes associated with protection against pregnancy 
associated diseases are located in the telomeric end of the KIR locus, and so our data are 
consistent with a model in which the population frequency of the centromeric end of the B 
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haplotype is maintained through protection against infectious disease.  A broad specificity of 
KIR2DS2 for different HLA-C allotypes complexed with peptides derived from pathogenic 
virus, provides a rationale for the evolution of this family of receptors.  Our observations, 
coupled with the recent discoveries of adaptive properties of NK cells, make them potential 
targets for novel therapeutic strategies against flaviviral infections.  
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Materials and methods 
Patients 
The cohort of HCV-exposed individuals was recruited from UK hepatology clinics (4, 38). 
Two hundred and thirty-three subjects had chronic HCV infection, and 128 had resolved 
infection.  Overall 239 (69%) were male, and 289 (82%) had acquired HCV through 
intravenous drug usage. 
 
HCV replicon 
The N17/JFH1 subgenomic replicon encoding the firefly luciferase reporter and the 
puromycin resistance marker has been described previously (21). Site-directed mutagenesis 
was performed using the QuikChange-XL-II kit (Agilent Technologies, Santa Clara, CA) with 
appropriate primers (sequences available upon request).  The N17 replicon RNAs were 
generated in vitro using the T7 Megascript kit (Applied Biosystems, Paisley, UK). To 
measure replication of N17 SGR/JFH1WT, 4 × 106 naive HUH7 cells were electroporated 
with 10 μg of viral RNA, cells were seeded in triplicate, lysed and luciferase activity 
measured using the Bright-Glo Luciferase assay system (Promega, Madison, WI). HUH7 
cells electroporated with the WT or the L9D variant of the N17 replicon RNA were cultured in 
the presence of 2 µg/ml puromycin (Life Technologies, Paisley, U.K.) and the surviving cells 
were pooled and established as stable replicon-expressing cell lines. 
 
Cell lines and transfectants 
721.174 and HUH7 cells were cultured in R10 medium (RPMI medium 1640 supplemented 
with 1% penicillin streptomycin [Life Technologies]) or DMEM and 10% FCS (Lonza, Slough, 
U.K.).  HLA-C*0102 or HLA-C*0304 were cloned into the pIB vector (39) and transfected into 
the HUH7.5 cells. The HEK:DENV replicon cells were grown in DMEM and 10% FCS 
supplemented with 2μg/mL puromycin.  The HLA-C*0304:ICP47 cell line was made by 
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transfecting 721.221:C*0304 cells with the ICP47 gene cloned into pCDNA 3.1 using the 
Polyplus jetPRIME® transfection system (SourceBioScience, Nottingham, UK) and selected 
using hygromicin 500µg/mL (Invivogen, CA).  The NKL cell line was transfected with the 
KIR2DL2, KIR2DS2 or KIR2DL3 cloned into the pIB vector as previously described. 
 
HUH7 cell lines stably expressing the WT N17 replicon or the L9D variant described above 
were transduced with pIB-HLA-C*0102 expressing lentiviral vector. The transduced cells 
were selected with 2μg/mL puromycin and 1 to 6μg/mL blasticidin. HUH7:C*0102:replicon 
cells were co-cultured with NKL cell lines for 24 hours at various E:T ratios for 24 hours, and 
then luciferase activity assessed. 
 
NK cell assays 
CD107a degranulation.  PBMCs were stimulated overnight with 1ng/mL rHuIL-15 (R&D 
Systems, Abingdon, U.K.). Peptides were synthesized by GL Biochem Ltd (Shanghai, China) 
or Peptide Protein Research (Fareham, U.K.). 721.174 cells were incubated with peptide at 
26°C overnight, washed, resuspended with the PBMCs at an E:T ratio of 5:1 and anti–
CD107a-AF647 (20μL/mL). Cells were then incubated at 26°C for 4hrs with 6μg/mL Golgi-
Stop (BD Biosciences, Oxford, U.K.) added after 1hr prior to staining and analysis by flow 
cytometry 
Cell tracker Orange (CTO) cytotoxicity assays. 721.174 cells were incubated with peptide at 
26 °C for 16hrs, then with CellTracker™ Orange CMTMR (Life Technologies) and 
resuspended with NK cell clones at an E:T ratio of 10:1. Co-cultures were incubated at 26°C 
for 4h, stained with Live/Dead fixable Aqua dead cell stain (Life Technologies) and fixed in 
1% (w/v) PFA prior to analysis by flow cytometry.  
LNP construct.  A construct expressing HLA-C*0102 in continuity with the 2A self-cleaving 
peptide sequence from Thosea asigna virus the E3/19K ER-targeting sequence and the 
 21 
LNPSVAATL or IVDLMACHATF peptide was synthesized from Gene Art™ (Life 
Technologies), cloned into the pIB vector and transduced into the 721.221 cell line.  
Inhibition of HCV replication assays. Target cells Huh7-J17-WT/HLA and Huh7-J17-R1/HLA 
were seeded. The next day, NKLs were co-cultured with the target cells in duplicate for 24 hr.  
Plates were then centrifuged and the cell pellet lysed with Glo Lysis Buffer (Promega). 50µl 
of each lysate was read using 50 µl of luciferase assay reagent Promega) on a GloMax® 
Discover Luminometer. 
HEK Cell Cytotoxic Killing Assay.  HEK and HEK:DENV cells were transiently transfected 
with 2ug of C*0102mCherry-pCDNA3 or C*0304mCherry-pCDNA3 using Polyplus jetPrime 
(SourceBioscience, UK). After 24 hours cells were co-cultured for 24 hours with NKL cell 
lines in triplicate at an E:T ratio of 6:1. Cells were stained with Live/Dead Zombie Violet stain 
(BioLegend, UK) for one hour, fixed with 1% paraformaldehyde-PBS solution and analyzed 
by flow cytometry. DENV-positive HEK cells were detected by the GFP expression of the 
DENV construct, and HLA-C*0102, or HLA-C*0304, transfected cell lines by mCherry 
expression. The percentage cytotoxicity was determined by calculating: the percentage of 
zombie violet positive cells in the presence of effectors minus the percentage of zombie 
violet positive cells in the absence of effectors. 
 
KIR staining 
The extracellular domain of KIR2DS2*001 or KIR2DL2*001 containing a C terminal 
biotinylation tag was cloned into pET23d+ vector. This was expressed as inclusion bodies in 
RosettaTM2 (DE3) bacteria (MerckMillipore, Feltham, U.K.), purified, denatured and reduced 
in 6M guanidine-HCL and 20mM DTT. KIR2DS2 was purified by gel filtration chromatography 
using FPLC. Biotinylation was performed using a BirA biotinylation kit (Avidity, Aurora, CO). 
Fluorescently-labeled tetramers were produced by coupling biotinylated KIR2DS2 molecules 
to PE-conjugated streptavidin (Molecular ProbesTM, Life Technologies).  The KIR2DS2*007 
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and KIR2DS2*008 tetramers were made from a KIR2DS2*001 template using the 
QuikChange Lightening Site-Directed Mutagenesis Kit (Agilent Technologies, Cheshire, UK), 
(primer sequences are available on request).  The KIR2DL2-IgG fusion construct (KIR2DL2-
Fc Chimera; R&D Systems Inc., Minneapolis, MN) was conjugated with protein A Alexa Fluor 
488 (Life Technologies).   
 
KIR genotyping 
KIR genotyping of the donors was performed by qPCR as previously described (4). 
 
NK cell clones 
NK cells (CD3- CD56+ CD158b+) were single cell sorted from PBMC from a KIR2DL2+S2+L3- 
donor into SCGM media (CellGenix, Freiburg, Germany) containing 5% heat-inactivated 
human serum and IL-12 (10 ng/mL) (Peprotech, NJ,), IL-15 (20 ng/mL) and IL-18 (100 
ng/mL) (both R&D Systems). Clones were fed weekly with irradiated PBMC (1 x 106/mL), 
250iu/ml IL-2 were and 2.5 μg/mL PHA (Fischer Scientific, Loughborough, U.K.). Clones 
were typed for expression of KIR2DS2 by RT-qPCR. RNA was extracted from the NK clones 
using TRIzol® (Life Technologies), reverse transcribed using a high capacity reverse 
transcriptase kit (Applied Biosystems).  1ng of cDNA was used for qPCR analysis. KIR2DS2, 
KIR2DL2, KIR2DL3 primers and probes were as described described (40).  Each sample 
was read in triplicate and gene expression was determined using the ΔCt method. 
 
Conjugate formation and staining 
721.174 cells were incubated overnight at 26°C in the absence or presence of 100μM 
peptide. 1 x 105 Ba/F3-KIR2DS2 or Ba/F3-KIR2DL2 cells (a gift from Dr Lewis Lanier) were 
co-incubated with the 721.174 cells at an E:T ratio of 2:1.  Cells were fixed in 4% (w/v) PFA 
in PBS and then stained with 20 μg/mL CD158b-PE (GL183) antibody (Beckmann Coulter, 
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High Wycombe, U.K.). Cells were imaged using a Leica SP5 resonance scanning 
microscope (Leica Microsystems, Milton Keynes, U.K.). Transmission images and PE 
emission were collected in different channels. Data were processed using Leica Imaging 
software and ImageJ software (http://imagej.nih.gov/ij). 
 
Immunoprecipitation and Western blotting 
721.174 cells were cultured with 20mM peptide overnight at 26°C. NKL-2DS2 and 721.174 
cells were coincubated at a 1:1 E:T ratio for 5 min at 37°C and lysed in 20mM Tris-HCl, 
pH7.6; 150mM NaCl; 1mM EDTA; 1mM sodium orthovanadate; and 0.5%Triton X-100. KIR 
were immunoprecipitated with anti-CD158b (clone GL183; AbD Serotec, Oxford, U.K.) and 
analyzed by Western blotting. Abs recognizing phospho-Vav1 (EP510Y; Abcam, Cambridge, 
U.K.), Vav1 (Cell Signaling Technology, Hitchin, U.K.), anti-phosphotyrosine (4G10 Platinum, 
Millipore), DAP-12 (clone D7G1X; Cell Signaling Technology), were used with HRP 
conjugated secondary Abs (Cell Signaling Technology, Hitchin, U.K.). Membranes were 
stripped using the Western blot Recycling Kit (Alpha Diagnostics, San Antonio, TX). Protein 
bands were detected by chemiluminescence (SuperSignal West Pico Chemiluminescent 
Substrate; Perbio Science, Cramlington, U.K.), using the ChemiDoc-It Imaging System with 
VisionWorks software (UVP), and quantified with ImageJ software. 
 
Peptide binding analysis 
The online resources ADT, Net-MHC pan and KISS were used to search for potential HLA-
C*0102 binding epitopes (41-43). 
 
Statistical Analysis 
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Statistical analyses (t-tests and ANOVA) were performed using GraphPad Prism®, version 6 
(La Jolla, CA) and logistic regression analysis performed using SPSS V20.0 (IBM, Armonk, 
NY). 
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Figure 1 
 
 
Figure 1. KIR2DS2 recognizes the HCV peptide LNPSVAATL 
1A PBMC were stimulated overnight with IL-15, and incubated for four hours with 721.174 
cells that had been loaded with VAPWNSFAL or with VAPWNSFAL plus the indicated HCV 
peptides at  concentration of 5µM.  The mean CD107a expression plus one standard error on 
CD3-CD56+CD158b+ NK cells from three unselected donors is shown.  1B-D CD107a 
degranulation assays of NK cells from KIR2DL2+/KIR2DS2+ and KIR2DL3+/KIR2DS2- donors 
in response to 721.174 cells incubated with indicated peptides.  Peptides were used at 5µM 
each. 1B shows flow cytometry histogram plots of CD107a expression gated on CD3-
CD56+CD158b+ NK cells from two donors of different KIR genotype.   The results from five 
donors of each genotype are summarized for CD158b+ NK cells in (1C) and for CD158b- NK 
cells in (1D).  Means and standard errors for each condition are shown.  P values indicate 
comparison to VAPWNSFAL alone.  1E,F NKL cells either untransfected or transfected with 
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KIR2DL2 or KIR2DS2 were incubated with 721.221 cells transfected with HLA-C*0102 or 
with HLA-C*0102+LNPSVAATL (C*0102-LNP) and the cytotoxicity of the 721.221 cells 
measured by flow cytometry. 1D shows flow cytometry histogram plots of the uptake of the 
Live/Dead fixable aqua dead dye by the target cells incubated with the indicated effector cells 
(1E).  The means and standard errors from three independent cytotoxicity experiments are 
shown in (1F).  Effector to target (E:T) ratios are also shown. P values indicate the 
comparison of cytotoxicity between the HLA-C*0102 and the HLA-C*0102-LNP targets.  
Where shown p values were determined by independent two-tailed t-tests (*p<0.05, 
**p<0.01,***p<0.001). 
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Figure 2 
 
 
 
Figure 2. LNPSVAATL activates KIR2DS2-postiive, but not KIR2DL2-positive, NK cells 
 
2A,B Ba/F3 cells expressing KIR2DS2 or KIR2DL2 were incubated with 721.174 cells loaded 
the indicated peptides.  Cells were fixed and stained with anti-CD158b prior to analysis by 
confocal microscopy (2A).  Peptides were used at a concentration of 100μM. Arrows indicate 
clustering at the interface between the cells Ba/F3 and 721.174 cells.  The intensity of 
staining of the Ba/F3 cell at the interface was compared with the membrane at a non-contact 
area, and plotted as the fold increase above background (2B).   The results from three 
independent experiments with a total of thirty conjugates per condition is shown.   The p 
value in comparison to 2DS2 with no peptide is shown.  2C NKL-2DS2 cells were incubated 
with 721.174 cells loaded with the indicated peptides and DAP12 was co-immunoprecipitated 
with anti-2DS2 antibody from the cell lysates prior to Western blot with anti-phosphotyrosine 
(pTyr) or anti-DAP12. DAP12 was also immunoprecipitated from NKL-2DS2 cells in the 
absence of 721.174 target cells (no target).  Densitometry results of the pDAP12/DAP12 ratio 
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from three independent experiments and p values in comparison to no peptide are shown. 
2D NKL-2DS2 or NKL-2DL2 cells were incubated with 721.174 cells loaded with the 
indicated peptides and Western blotting for phospho-Vav1 (pVAv1) or Vav1 performed.  “No 
target” lanes indicate immunoprecipitation from NKL-2DS2 or NKL-2DL2 cells alone.  
Densitometry results of the phospho-Vav1/Vav1 ratio from three independent experiments 
and p values in comparison to no peptide are shown.  2E 721.174 cells were cultured with 
100μM peptide (VAWPNSLSL or LNPSVAATL) overnight then stained with the KIR2DL2-Fc 
fusion construct and analyzed by flow cytometry.  Shown are the histogram plots for the two 
peptides (filled histograms) and the median fluorescence of KIR2DL2-Fc, compared with no 
peptide (open histograms).  For all panels p values were derived using one-way ANOVA with 
Dunnett’s test for multiple comparisons (*p<0.05, ****p<0.0001). 
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Figure 3 
 
 
Figure 3. Endogenously presented LNPSVAATL is recognized by KIR2DS2 in the 
context of HCV  
3A HUH7 cells expressing the N17 (JFH1ΔE1E2-luc) replicon with (right panel) or without 
(left panel) HLA-C*0102 were co-incubated with NKL, NKL-2DL2 or NKL-2DS2 cells at the 
indicated E:T ratios.   Luciferase activity from the co-cultures was measured and normalized 
to expression in the absence of NKL cells.  The relative inhibition of replication was then 
measured.  The means and standard errors of three experiments performed in duplicate are 
shown.  Comparisons for NKL-2DS2 with NKL-2DL2 are indicated. 3B Replication of wild 
type (WT) N17 (JFH1ΔE1E2-luc) replicon RNA, or variants in which the LNPSVAATL epitope 
had been mutated to aspartate at residues 3, 7, 8, 9 (P3D, A7D, T8D and L9D respectively).  
As a non-replicating control (Control), the N17 replicon carrying the lethal GND mutation in 
the viral NS5B protein was used.  3C  NKL, NKL-2DL2 or NKL-2DS2 cells were co-cultured 
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with HUH7-C*0102 cells expressing either wild-type (WT) or the L9D mutant HCV replicon.  
Luciferase activity was measured and plotted as percentage inhibition of viral RNA 
replication compared to HUH7 cells incubated in the absence of NKL cells. Shown are the 
means and standard errors of three experiments performed in duplicate and p values for 
comparisons between NKL-2DS2 and NKL-2DL2.  3D NKL, NKL-2DL2 or NKL-2DS2 cells 
were co-cultured with HUH7-C*0304 cells expressing either wild-type (WT) (left panel) or the 
L9D mutant HCV replicon (right panel).  The percentage inhibition of replication compared to 
the no NKL control is shown.  Statistical analyses for 3A,C,D were performed using 
independent two-tailed t-tests to compare NKL-2DS2 and NKL-2DL2.  3E, F 
721:C*0304:ICP47 cells were loaded with the indicated peptides at saturating concentrations 
(100μM) and then stained for HLA-C expression using the DT9 antibody (3E) or the 
KIR2DS2-PE tetramer (3F).  One representative histogram plot from three independent 
experiments is shown for each peptide and the median fluorescence intensity of staining 
indicated.  Dark lines indicate peptide staining compared to the no peptide control (gray 
lines).   3G Western blot for phospho-Vav1 and Vav1 from 721.221:C*0304:ICP47 cells 
cultured with 20μM of the indicated peptide and co-incubated with NKL-2DS2 cells at a 1:1 
E:T ratio.  One representative blot is shown together with densitometry of the phospho-
Vav1/Vav1 ratio (mean+SD) from three independent experiments.  Statistical analysis was 
performed using one-way ANOVA with Dunnett’s test for multiple comparisons (*p<0.05, 
**p<0.01,***p<0.001). 
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Figure 4 
 
Figure 4: Protein sequence alignment of the NS3 helicase-encoding region of 63 
Flaviviruses demonstrate conservation of a KIR2DS2-binding peptide 
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The box indicates the putative KIR2DS2 binding peptide. Numbering is from the start of the 
NS3 protein of Dengue virus. 
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Figure 5 
 
 
 
Figure 5. KIR2DS2 recognizes conserved helicase peptides from multiple flaviviruses  
5A KIR2DS2 tetramer (black lines) binding to 721.174 cells incubated with the indicated 
peptides at saturating concentrations (200µM) as compared to no peptides (grey lines).  The 
median fluorescence of tetramer staining of peptide is indicated (JEV:Japanese Encephalitis 
virus).  5B NKL-2DS2 cells were incubated with 721.174 cells pre-loaded with the indicated 
Flavivirus peptides and then assayed for phospho-Vav1 and Vav1 by Western blotting.  One 
representative blot of each is shown.  5C The peptide IVDLMCHATF (IVDL) was co-
expressed with HLA-C*0102 in 721.221 cells and used as targets in cytotoxicity assays in 
which effector cells were NKL, NKL-2DL2 and NKL-2DS2.  Experiments were performed at 
an effector to target ratio of 6:1 and comparisons were made between the HLA-C*0102 
transfectant and the HLA-C*0102:LNP or HLA-C*0102:IVDL cells. 5D-F  HEK, HEK-C*0102 
or HEK:C*0304 cells expressing a dengue virus replicon (HEK:DENV, HEK:C*0102:DENV or 
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HEK:C*0304:DENV, respectively) or not were co-cultured with NKL cells expressing 
KIR2DS2 or KIR2DL2 and cytotoxicity assessed at 24 hours.  The effect of dengue virus on 
KIR2DS2-mediated killing is shown in 5D and the effect of HLA-C*0102 on KIR2DS2-
mediated killing in 5E and Fig S5.  5F compares the effect of HLA-C*0304 on killing of DENV 
cells with that of HLA-C*0102 by NKL-2DS2.  Means and standard errors of at least three 
independent experiments performed in triplicate are shown.  5G Comparison of HCV (left 
panel) and Dengue NS3 helicases (right panel) showing contact of the LNPSVAATL (HCV) 
and IVDLMCHATF (Dengue) epitopes with the nucleic acid within the helicase domain 
(yellow).  Selected amino acids from the epitopes are illustrated.  Images were derived from 
structures published by Gu and Rice, and Luo et al and rendered using PyMOL (25, 29). 
Where shown p values were determined by independent two-tailed t tests (*p<0.05, 
***p<0.001). 
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Table 1. 
Genetic association of activating KIR with their putative ligands and the outcome of HCV 
infection in 336 individuals exposed to HCV (216 chronically infected and 120 with resolved 
HCV infection). Logistic regression was performed using SPSS v20.0 using the ENTER 
method.  OR>1 indicates protection against chronic HCV infection. 
 
 P OR 95%CI 
KIR2DL3/L3:HLA-C1/C1 0.005 2.68 1.34-5.37 
KIR3DS1:HLA-BBw4 0.032 2.16 1.07-4.37 
KIR2DS2:HLA-C1 0.033 2.06 1.06-4.02 
KIR2DS3 0.033 0.51 0.27-0.95 
KIR2DS1:HLA-C1 0.170 0.59 0.28-1.25 
KIR2DS2:HLA-A*11 0.394 0.64 0.23-1.78 
KIR2DS1:HLA-C2 0.509 0.74 0.31-1.80 
KIR2DS2:HLA-C2 0.727 1.13 0.58-2.18 
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Supplementary materials 
Figure S1: Peptide stabilization of HLA-C*0102 by HCV peptides  
721.174 cells were incubated with the indicated peptides overnight at 26°C and then stained 
with the VP6G3 antibody and analyzed by flow cytometry.  The median fluorescence 
intensity (MFI) was plotted at the different peptide concentrations.  VAPWNSLSL is a 
naturally processed and presented self-peptide used as a positive control. 
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Figure S2:  The effects of single HCV peptides on degranulation of CD158b NK cells: 
721.174 cells were incubated with the indicated HCV peptides (100μM) and were then used 
as target cells in CD107a assays from NK cells from three unselected donors.  Shown is the 
expression of CD107a on CD158b+ (KIR2DL2/L3/S2+) CD3-CD56+ NK cells. 
 
 
 
  
N
o 
pe
pt
id
e
VA
PW
N
SF
A
L
LL
PR
R
G
PR
L
LL
PR
R
G
PK
L
LS
PR
PV
SY
L
LS
R
H
YK
VF
L
LN
PS
VA
A
TL
VL
PC
SF
TT
L
A
R
PD
YN
PP
L
R
A
YL
N
TP
G
L
0
10
20
30
40
50
%
C
D
10
7a
 3 
 
Figure S3:  Cytotoxicity of KIR2DS2+ NK cell clones to peptide loaded 721.174 cells  
Figure S3A Cell tracker orange (CTO) cytotoxicity assay of 721.174 cells incubated with 
either no peptide, LNPSVAATL (LNP) or VAPWNSFAL (VAP-FA) and four NK cell clones 
(three KIR2DS2+ and one KIR2DS2-) at an effector:target ratio of 6:1.  Target cells were 
labeled with CTO and following incubation with NK cell clones for four hours, stained with 
Live/Dead fixable Aqua dead cell stain.  Peptides were used at 100μM. 
 
Figure S3B Dot plots for one KIR2DS2+ NK cell clone.  Plots are gated on CTO-positive 
target cells. 
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Figure S4: KIR2DS2-tetramer binding to HLA-C*0102 and HCV peptides or 
VAPWNSLSL peptide derivatives 
721.174 cells were cultured overnight with 100μM of the indicated peptides overnight then 
stained with the KIR2DS2-tetramer and analyzed by flow cytometry.   
 
Figure S4A: Histogram plots for the peptides (red) in comparison to the no peptide control 
(blue) and the median fluorescence of staining is indicated. 
 
Figure S4B:  Summary of three independent KIR2DS2-tetramer binding experiments.  The 
fold increase in binding compared to the no peptide control is indicated: Significant increases 
in binding compared to the naturally eluted peptides VAPWNSLSL, were noted for the 
LNPSVAATL peptide and also VAPWNSLSL derivatives with AT at P7 and P8 respectively.  
*p<0.05, **p<0.001, ***p<0.001 as determined by one-way ANOVA and Dunnett’s test for 
multiple comparisons. 
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Figure S5:  Flow cytometry plots comparing binding of KIR2DS2*001, KIR2DS2*007  
and KIR2DS2*008 binding to HLA-C*0102 and peptide 
721.174 cells were cultured overnight with 100μM of the indicated peptides, then stained with 
the indicated KIR2DS2-tetramers and analyzed by flow cytometry.  Histograms show binding 
of tetramers to peptide loaded 721.174 cells (black lines) compared with the no peptide 
control (gray lines).  The median fluorescence intensity of tetramer binding to peptide loaded 
721.174 is indicated. 
 
 
 
 
  
No Peptide VAPWNSFAL LNPSVAATL IVDLMCHATF VIDAMCHATL IVDVMCHATL
KIR2DS2*001
KIR2DS2*007
KIR2DS2*008
1613
1874
1860
1856 2883 5640 2737 2876
2061 3239 7153 3203 3289
2052 3223 6442 3250 3417
Tetramer-PE
C
ou
nt
 6 
Figure S6: Analysis of viral RNA and protein production in DENV replicon containing 
cells compared to DENV-2 infected cells.  
HEK293T cells either infected with DENV-2 (moi=1), stably expressing a DENV-2 replicon 
(Rep-DV), or mock infected were harvested at the indicated time points after infection (or the 
corresponding time points for the replicon and mock infected cells) and used for total RNA 
and protein extraction.  
 
Fig. S6A: 1 ug of RNA was used for qRT-PCR using the 2X SYBR Green/ROX qPCR 
Master Mix. The qRT-PCR reaction was performed using the Stratagene MX3005P QPCR 
System. The Ct (cycle threshold) value for each sample was used for RNA quantification. 
The ratio of DENV-2 NS5 target gene expression was defined as fold change in target gene 
expression divided by fold change in reference gene (ACTB) expression.  
 
  
hr post-infection (p.i.)
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Fig. S6B: Proteins in total cell lysates prepared from the cell samples were separated by 
12% SDS-PAGE and analysed by Western blot using anti-NS5 rabbit and anti-GAPDH 
mouse primary antibodies, a HRP-conjugated anti-rabbit / mouse IgG secondary antibody 
and a chemiluminescence detection system. The amount of GAPDH was determined as a 
loading control. The sizes of relevant molecular weight markers (in kDa) are shown. 
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Figure S7:  Flow cytometry plots illustrating gating strategy and killing of HEK cells 
expressing GFP-tagged Dengue virus replicon by NKL-2DS2 cells 
HEK cells expressing a dengue virus replicon (HEK:DENV) or HEK-C*0102 cells 
(HEK:C*0102) expressing a dengue virus replicon (HEK:C*0102:DENV) were co-cultured 
with NKL cells expressing KIR2DS2 or KIR2DL2 and cytotoxicity assessed at 24 hours using 
a zombie violet live/dead stain.  For the comparison of HEK:C*0102 and HEK:C*0102:DENV, 
target cells were gated on HLA-C*0102mCherry (S7A) and for comparison of HEK:DENV 
with HEK:C*0102:DENV, target cells were gated on dengue-FITC (S7B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure S7A 
Figure S7B 
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Table S1: 
Summary of hepatitis C virus (HCV) peptides identified to bind HLA-C*0102 using the 
indicated algorithms and compared to the naturally eluted peptide VAPWNSLSL.  The 
genotype 1b virus was used as the template for the screen. Net MHC Pan score is shown as 
binding affinity, a KISS score of 1 corresponds to binding and of 0 to no binding and for the 
ADT binding energies a lower score indicates better binding52-54. 
 
Peptides Protein Net MHC Pan 
peptide binding 
affinity (nM) 
KISS 
Score 
ADT 
(Binding 
Energies) 
VAPWNSLSL Host TIMP1  22.70 1 5.919544 
VLPCSFTTL HCV E2  199.73 1 10.485140 
LNPSVAATL HCV NS3 1306.03 0 7.113784 
LSPRPVSYL HCV NS3 276.65 0 7.147722 
LLPRRGPRL HCV Core 296.22 1 8.483209 
RAYLNTPGL HCV NS3 250.21 1 5.517011 
AQPGYPWPL HCV Core 1899.79 1 7.790346 
ARPDYNPPL HCV NS5A 4401.92 1 7.753846 
LSPHYKVFL HCV NS2 5333.43 1 7.521453 
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Table S2: 
Protein sequence alignment of hepatitis C viruses derived from consensus sequences from 
the Los Alamos HCV sequence database (http://hcv.lanl.gov/).  The LNPSVAATL epitope is 
indicated. 
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Table S3: 
Flavivirus NS3 HLA-C*0102 binding peptides with an “AT” motif at the C terminus minus one 
and two positions as determined by NetMHCpan 2.8. The naturally eluted self-peptide and 
HCV NS3 peptide are shown for comparison.  Numbering is from the start of the NS3 region. 
A higher prediction score and a lower percent rank are more likely to be associated with HLA 
class I binding. 
Peptide ID 
Prediction 
score 
Affinity 
(nM) 
Percent  
Rank 
VAPWNSLSL TIMP1125-133 0.4686 314.1935 0.01 
IVDVMCHATL 
Japanese 
encephalitis343-352 0.2883 2210.1042 0.3 
IVDVMCHATL West Nile virus343-352 0.2883 2210.1042 0.3 
VIDAMCHATL Yellow fever338-347 0.277 2495.4788 0.4 
IVDLMCHATF Dengue255-264 0.2301 4146.1392 1 
IVDLMCHATF Zika310-319 0.2301 4146.1392 1 
LNPSVAATL HCV228-236 0.1952 6051.6265 2 
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Table S4: Accession numbers used to compile the Flavivirus sequence alignment in Figure 4 
Virus Gene/protein bank accession 
number 
Absettarov tick-borne encephalitis  AHM02467.1 
Alfuy  AAX82481.1 
Apoi  NP_775684.1 
Aroa  AIU94739.1 
Bagaza  AEI27245.1 
Banzi  ABI54472.1 
Bouboui  ABI54473.1 
Bussuquara  AAV34152.1 
Cacipacore  YP_009126874.1 
Cowbone Ridge  AAQ14430.1 
Dakar bat  AAQ14431.1 
Dengue  ACK57817.1 
Edge-Hill               ABI54476.1 
Entebbe bat YP_950477.1 
Gadgets Gully ABB90669.1 
Hypr Tick-borne encephalitis  AKP16370.1 
Ilheus    AGJ84083.1 
Israel turkey meningoencephalomyelitis  AGV15509.1 
Japanese encephalitis  ABU94628.1 
Jugra ABI54482.1 
Jutiapa AJA91182.1 
Kadam   ABB90670.1 
Karshi  YP_224133.1 
Kedougou    YP_002790882.1 
Kokobera  AAV34157.1 
Koutango ABW76844.2 
Kumlinge tick-borne encephalitis  ALP82437.1 
Kunjin  Pdb:2QEQ 
Kyasanur   ADH95737.1 
Langat NP_740299.1 
Louping ill NP_740726.1 
Meaban ABB90668.1 
Modoc   AAQ14433.1 
Motana myotis leukoencephalitis NP_775649.1 
Murray Valley encephalitis PDB: 2WV9_A 
Naranjal  AIU94742.1 
Negishi  ALP82435.1 
Ntaya YP_006846328.2 
Omsk hemorrhagic fever  NP_878909.1 
Phnom Penh bat AJA91183.1 
Powassan NP_775520.1 
Rio Bravo NP_776076.1 
Rocio  AAV34158.1 
Royal farm ABB90673.1 
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Saboya  AAQ14435.1 
Sal Vieja AAQ14429.1 
Saumarez Reef ABB90674.1 
Sepik   YP_950478.1 
Sokoluk  AHL27154.1 
Spondweni  ABI54480.1 
St. Louis encephalitis AGE00046.1 
Stratford  AIU94744.1 
Tembusu AGU68254.1 
Tick borne encephalitis             AEQ77280.1 
Tyuleniy AHH82586.1 
Uganda S                ABI54481.1 
Usutu YP_164814.1 
Wesselsbron AFK88571.1 
West Nile               AFI56984.1 
Yaounde ABW76843.2 
Yellow-fever            AIZ07887.1 
Yokose BAC79364.1 
Zika BAP47441.1 
 
 
 
